CliffBio
biologic

Skyrizi

risankizumab-rzaa

Loss of exclusivityJune 2034projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameSkyrizi
Active ingredientrisankizumab-rzaa
Strength360MG/2.4ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2022
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Skyrizi patent cliff — loss of exclusivity June 2034 | CliffBio